Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab Combined With Metronomic Chemotherapy in Advanced SCLC
NCT07698054Phase 2Not yet recruiting
- Sponsor
- Henan Cancer Hospital
- Start
- Aug 2026
- Primary completion
- Jan 2030
01
Overview
Phase 2, randomised, open-label trial of toripalimab in small cell lung cancer (SCLC) (5 arms), sponsored by Henan Cancer Hospital. Primary endpoint: Objective Response Rate at 100 months. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
toripalimab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT07698054.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07698054.